Latest Sustainability News

Resonance Health has revealed ambitious growth plans at its 2025 AGM, projecting revenue to nearly quadruple by FY26 while maintaining positive EBITDA guidance. The company is broadening its global footprint and diversifying its clinical trial services across multiple therapeutic areas.

Shaver Shop Group Limited reported steady sales of $219 million for FY25, with a notable 2.1% rise in gross profit driven by its private brand Transform-U. The company’s strategic focus on exclusive products and store network optimization sets a positive tone for 2026.

Stellar Resources has raised an extra A$500,000 through a placement to a major shareholder, adding to a recent $12.4 million capital influx aimed at advancing its Heemskirk Tin Project in Tasmania amid robust tin market demand.

Superloop Limited has reported a robust FY25 performance with significant revenue and profitability gains, marking its entry into the ASX 200 index and advancing key ESG initiatives.

Comms Group Limited reports a strong start to FY26 with a 41.6% revenue increase and successful integration of TasmaNet, positioning the company for ambitious annual targets.

NEXTDC reported robust FY25 results with 14% revenue growth and unveiled an ambitious 3GW expansion pipeline across Australia and Asia, positioning itself at the forefront of the AI infrastructure revolution.

Superloop Limited has delivered a standout FY25 with strong revenue growth and a positive net profit after tax, accelerated by strategic acquisitions and market share gains. The company sets an ambitious FY26 guidance, underpinned by a new $300 million loan facility and expanding fibre footprint.

NEXTDC’s 2025 AGM highlights a landmark year with 42% growth in contracted utilisation and a $6.4 billion funding base, alongside strategic board changes and a new incentive plan to secure leadership.

NEXTDC’s FY25 Annual General Meeting reveals robust financial growth, significant data centre expansions, and enhanced funding capacity to capitalise on AI infrastructure demand.

ReNerve Limited’s innovative NervAlign® Nerve Cuff has secured approval for use across the US Department of Defense and Veterans Affairs healthcare systems, marking a major milestone for the Australian medtech company.

ECS Botanics has successfully raised nearly A$2 million through a placement aimed at accelerating its international expansion and product development. The move underscores growing investor confidence in the medicinal cannabis company’s strategic growth plans.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.